This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Women's Health Initiative Study of Cognitive Aging (WHISCA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Sally A Shumaker, Wake Forest University Health Sciences
ClinicalTrials.gov Identifier:
NCT00631332
First received: February 28, 2008
Last updated: June 15, 2017
Last verified: June 2017
  Purpose
The Women's Health Initiative Study of Cognitive Aging (WHISCA) is a two-armed, randomized, placebo controlled, clinical trial designed to assess the efficacy of postmenopausal hormone therapy (HT) on age related changes in specific cognitive functions.

Condition
Healthy

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Other
Official Title: Effects of Hormone Replacement Therapy on Cognitive Aging: Women's Health Initiative Study of Cognitive Aging (WHISCA)

Resource links provided by NLM:


Further study details as provided by Sally A Shumaker, Wake Forest University Health Sciences:

Primary Outcome Measures:
  • Determine if HT protect against age-associated memory and cognitive longitudinal decline in women age 65 and older as measured over time by a series of cognitive tests administered annually. [ Time Frame: Annual assessment done annually. ]
    The primary outcome measures are the changes in scores from a standardized neuropsychological assessment will be conducted annually. The battery is comprised primarily of tests of memory, and includes the following tests in specified order: the Prospective Memory Tests, Primary Mental Abilities Vocabulary Test, the California Verbal Learning Test, the Benton Visual Retention Test, Card Rotations Test, the Finger Tapping Test, the Letter and Semantic Fluency Test and the Digit Span Test. In addition, the Positive and Negative Affect Scale and Geriatric Depression Scale will be administered.


Secondary Outcome Measures:
  • Determine the long-term effects of HT on changes in memory, other cognitive functions, and affect; and to investigate predictors of the transitions between normal aging and mild cognitive impairment and mild cognitive impairment and dementia. [ Time Frame: measured over life of the study ]
    Secondary outcome measures will examine relative differences in measures between enrollment in WHIMS and the termination of the WHIMS E+P trial and E-Alone trial and also examine the relative differences in measures comparing periods of time for each woman when she reported taking HT versus times she reported not taking HT.


Enrollment: 2303
Study Start Date: July 1999
Study Completion Date: June 2008
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Detailed Description:

WHISCA is an ancillary study to the Women's Health Initiative (WHI) and the WHI Memory Study (WHIMS) and has enrolled 2303 women aged 66 to 84 years who did not meet the criteria for dementia. WHISCA is investigating the effects of hormone therapy on rates of change over time in memory, other aspects of cognition (language, attention, spatial ability), motor function, and mood.

Objectives

  • Does HT protect against age-associated memory and cognitive longitudinal decline in women age 65 and older?
  • What is the rate of change in memory and other cognitive abilities in women receiving HT compared to women receiving placebo?
  • Does the addition of progesterone to HT modify the effects of estrogen on memory and other cognitive abilities?
  Eligibility

Ages Eligible for Study:   65 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
A subset of women who were enrolled in the Women's Health Initiative Memory Study (WHIMS), who are at least 65 years old and not diagnosed with any type of dementia.
Criteria

Inclusion Criteria:

  • Enrolled in WHIMS
  • At least 65 years old
  • Not diagnosed with dementia

Exclusion Criteria:

  • Women younger than 65 years of age
  • Have dementia
  • not enrolled in WHIMS
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00631332

Locations
United States, North Carolina
Wake Forest University School of Medicine
Winston-Salem, North Carolina, United States, 27157
Sponsors and Collaborators
Wake Forest University
Investigators
Principal Investigator: Sally Shumaker, PhD Wake Forest University Health Sciences
  More Information

Publications:

Responsible Party: Sally A Shumaker, Professor, PHS-Social Sciences, Wake Forest University Health Sciences
ClinicalTrials.gov Identifier: NCT00631332     History of Changes
Other Study ID Numbers: NO1-AG-9-2115
Study First Received: February 28, 2008
Last Updated: June 15, 2017
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: WHISCA will follow guidelines, methods and processes as set forth in the WHI 2015-2020 Data Sharing Plan. Accompanying the limited data sets, substantial electronic documentation will be provided in a standard format that is readable on a variety of platforms. Documentation will include data collection forms, a description of study protocol and procedures, description of all variable re-coding and a list of major study publications. These data will be available to users only under a data-sharing agreement that provides for: a commitment to using the data only for research purposes and not to identify any individual participant; a commitment to securing the data using appropriate computer technology; and a commitment to destroying or returning the data after analyses are completed. Data will be made available for timely release no later than the acceptance for publication of the main findings from the final dataset.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Sally A Shumaker, Wake Forest University Health Sciences:
women, dementia, cognition.
non-demented women at least age 65

ClinicalTrials.gov processed this record on June 23, 2017